Prostate Cancer from a Nuclear Oncology Perspective

• Verfasst von: Kairemo, Kalevi [VerfasserIn]
• Titel: Prostate Cancer from a Nuclear Oncology Perspective
• Titelzusatz: A Personal Journey
• Verf.angabe: by Kalevi Kairemo
• Ausgabe: 1st ed. 2025.
• Verlagsort: Cham
• Verlagsort: Cham
• Verlag: Springer Nature Switzerland
• Verlag: Imprint: Springer
• E-Jahr: 2025
• Jahr: 2025.
• Jahr: 2025.
• Umfang: 1 Online-Ressource(XV, 233 p. 92 illus., 74 illus. in color.)
• ISBN: 978-3-031-90337-3
• DOI: doi:10.1007/978-3-031-90337-3
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• K10plus-PPN: 1926115139
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext
• Lokale URL UB: Bibliothek der Medizinischen Fakultät Mannheim der Universität Heidelberg
• Bibliothek/Idn: UW / m4726196812
• Lokale URL Inst.: Zum Volltext

Abstract

1. Introduction – prostate cancer from the point of view of the author and the history of imaging -- 2. Integrated summary of research on radioiodinated estramustine phosphate and estramustine binding protein antibody in prostate cancer treatment -- 3. Summary of Diagnostic Accuracy of 18F-Fluorocholine PET/CT in Prostate Cancer Staging -- 4. Overview of 18F-NaF PET/CT Imaging -- 5. 18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer -- 6. PSMA-PET in prostate cancer -- 7. 18F-FLT PET/CT in Prostate Adenocarcinoma -- 8. 18F-FDHT-PET Imaging in the Management of Hormone-Dependent Prostate Cancer -- 9. Immunoscintigraphy and radioimmunotherapy of prostate cancer incuding own personal journey -anti-PAP and anti-PSMA antibodies -- 10. Briefly about radiation therapy -- 11. PET/CT for Radiation Therapy Planning of Prostate Cancer -- 12. Brief overview of prostate cancer treatment modalities -- 13. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer -- 14. Lu-177-PSMA treatment in prostate cancer -- 15. Clinical Experience in 225Ac-PSMA -- 16. Multicenter trials prostate radioligand therapy (PRLT) in castration resistant cancer -- 17. Meta-analyses and systematic reviews (own experience) in prostate cancer -- 18. Own history of cancer suspicions -- 19. Public appearance because of nuclear oncology (pictorial essay) -- . Appendix - ISUP and PI-RADS classifications.

Abstract

Provisional text This book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na18F, 18F-FCH, 18F-FACBC, 68Ga-PSMA11, 18F-PSMA-1007, and 18F-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors´ practice radiation therapy has been more important and surgical applications; therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as 89SrCl2, 186ReHEDP, 153SmEDTMP, 117mSnDTPA, and 223RaCl2, and targeted treatments (177Lu-PSMSA-617, 177Lu-PSMA-I&T and 225Ac-PSMA). Thanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author's involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience. This book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author's extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.